Cegedim Dendrite expands Alliance Program three ways

Cegedim Dendrite has announced the expansion of its Alliance Program at the eyeforpharma Sales Force Effectiveness Europe 2009 Conference in Barcelona, Spain. 


Cegedim Dendrite is expanding formal partnerships with selected technology, software and consulting companies in order to provide additional capabilities and services to customers. Cegedim Dendrite a provider of customer relationship management solutions to the pharmaceutical industry. 


The Alliance Program will accommodate three different types of businesses.


Technology Partners are companies that offer technology and platform solutions that support and enhance the performance of Cegedim Dendrite business applications. Software Partners are companies with software products that complement Cegedim Dendrite's applications. Consulting Partners provide a range of services associated with the optimal use of Cegedim Dendrite products and services. 


Laurent Labrune, chief executive officer at Cegedim Dendrite said that an open business model —particularly partnerships with other industry leaders—fosters innovation and improved customer satisfaction. He added that Cegedim Dendrite will be building strong partnerships with other best-of-breed companies that have offerings that complement Cegedim Dendrite products and services so that the company can give its customers a technological edge in a very competitive market. 


Cegedim Dendrdite officials believe that with the open model, industry-leading solutions would be enhanced by strategic alliances which would ensure the availability of complementary products and services aimed at delivering total customer satisfaction.

You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.